MA43733A - Composés cinnolin-4-amine et leur utilisation pour traiter le cancer - Google Patents
Composés cinnolin-4-amine et leur utilisation pour traiter le cancerInfo
- Publication number
- MA43733A MA43733A MA043733A MA43733A MA43733A MA 43733 A MA43733 A MA 43733A MA 043733 A MA043733 A MA 043733A MA 43733 A MA43733 A MA 43733A MA 43733 A MA43733 A MA 43733A
- Authority
- MA
- Morocco
- Prior art keywords
- cinnolin
- amine compounds
- treat cancer
- cancer
- treat
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DODZTSARNRLOKY-UHFFFAOYSA-N cinnolin-4-amine Chemical class C1=CC=C2C(N)=CN=NC2=C1 DODZTSARNRLOKY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310883P | 2016-03-21 | 2016-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43733A true MA43733A (fr) | 2018-11-28 |
Family
ID=58361025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043733A MA43733A (fr) | 2016-03-21 | 2017-03-20 | Composés cinnolin-4-amine et leur utilisation pour traiter le cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190099421A1 (fr) |
| EP (1) | EP3433251A1 (fr) |
| JP (1) | JP2019512512A (fr) |
| KR (1) | KR20180127419A (fr) |
| CN (1) | CN108884084A (fr) |
| AR (1) | AR107937A1 (fr) |
| AU (1) | AU2017237394A1 (fr) |
| BR (1) | BR112018068347A2 (fr) |
| CA (1) | CA3017035A1 (fr) |
| CO (1) | CO2018010951A2 (fr) |
| DO (1) | DOP2018000197A (fr) |
| IL (1) | IL261648A (fr) |
| MA (1) | MA43733A (fr) |
| MX (1) | MX2018011283A (fr) |
| PE (1) | PE20181895A1 (fr) |
| SG (1) | SG11201806982PA (fr) |
| TW (1) | TW201808939A (fr) |
| WO (1) | WO2017162605A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| KR20200131270A (ko) * | 2018-03-14 | 2020-11-23 | 메르크 파텐트 게엠베하 | 대상체에서의 암을 치료하기 위한 화합물 및 이의 용도 |
| ES3001444T3 (en) * | 2018-09-14 | 2025-03-05 | Suzhou Zanrong Pharma Ltd | 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
| CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DK0880508T3 (da) | 1996-02-13 | 2003-06-30 | Astrazeneca Ab | Quinazolinderivater som VEGF-inhibitorer |
| CN1116286C (zh) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-苯胺基喹唑啉衍生物 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| WO2012101062A1 (fr) | 2011-01-28 | 2012-08-02 | Novartis Ag | Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations |
| CA2837199A1 (fr) * | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Composes de cinnoline comme inhibiteur de l'activite de la kinase lrrk2 |
| NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/fr not_active Ceased
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko not_active Withdrawn
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 CA CA3017035A patent/CA3017035A1/fr not_active Abandoned
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/fr not_active Withdrawn
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019512512A (ja) | 2019-05-16 |
| DOP2018000197A (es) | 2018-10-15 |
| MX2018011283A (es) | 2019-05-27 |
| US20190099421A1 (en) | 2019-04-04 |
| WO2017162605A1 (fr) | 2017-09-28 |
| AR107937A1 (es) | 2018-06-28 |
| SG11201806982PA (en) | 2018-09-27 |
| CO2018010951A2 (es) | 2018-10-22 |
| EP3433251A1 (fr) | 2019-01-30 |
| IL261648A (en) | 2018-10-31 |
| BR112018068347A2 (pt) | 2019-01-15 |
| CA3017035A1 (fr) | 2017-09-28 |
| AU2017237394A1 (en) | 2018-11-01 |
| TW201808939A (zh) | 2018-03-16 |
| CN108884084A (zh) | 2018-11-23 |
| PE20181895A1 (es) | 2018-12-11 |
| KR20180127419A (ko) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
| EP3265113A4 (fr) | Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer | |
| MA47440A (fr) | Sulfonylurées, composés apparentés, et leur utilisation | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| EP3307876A4 (fr) | Cellules nk-92 modifiées pour traiter le cancer | |
| EP3370726A4 (fr) | Utilisation d'agonistes de tlr8 pour traiter le cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA45709A (fr) | Composés diazahétérobicycliques substitués et leur utilisation | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| MA45613A (fr) | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique | |
| MA43364A (fr) | Composés d'alcènes tétrasubstitués et leur utilisation | |
| EP3288592A4 (fr) | Utilisation de cannabidiol pour le traitement de spasmes infantiles | |
| EP3148536C0 (fr) | Associations pharmaceutiques pour traiter le cancer | |
| EP3411035A4 (fr) | Composés aminothiazole et leur utilisation | |
| MA71411A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3317274A4 (fr) | Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3250035A4 (fr) | Composés et leur utilisation en tant qu'inhibiteurs de bace1 | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| EP3589659A4 (fr) | Composés et méthodes de traitement du cancer | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP2953938A4 (fr) | Composés de benzopyrane fonctionnalisés et leur utilisation | |
| EP3347025A4 (fr) | Méthodes et compositions pour le traitement du cancer |